EBITDA margin hit an unprecedented -4.5% with FCF at -NZ$195.0m
Continuing-operations EBITDA swung to a NZ$34.7m loss while Synlait disposed of North Island assets and withdrew FY26 guidance.
Published 23 April 2026
Read briefingCompany archive
Read that company's published results in release order, newest first.
Showing 1-8 of 8 published briefings.
Continuing-operations EBITDA swung to a NZ$34.7m loss while Synlait disposed of North Island assets and withdrew FY26 guidance.
Published 23 April 2026
Read briefingOperating cash flow stayed negative at -$12.0m and a tax credit lifted reported NPAT, leaving the durability of the turnaround as the open question.
Published 23 April 2026
Read briefingEBITDA margin collapsed to an unprecedented 3.0% on a 15.2% revenue decline, leaving the balance sheet under acute refinancing pressure.
Published 23 April 2026
Read briefingContinuing operations swung to a $14.1m loss as a Dairyworks discontinued-operation gain partly cushioned reported NPAT.
Published 23 April 2026
Read briefingFY23 NPAT guidance cut to a NZ$(5)m–NZ$5m range as inventory build pushes net debt/EBITDA to 10.04x and Advanced Nutrition demand softens.
Published 23 April 2026
Read briefingEBITDA rose 43.4% to NZ$68.4m but the unprecedented NZ$117.3m operating cash flow leans on a working-capital release that may not repeat.
Published 23 April 2026
Read briefingRevenue rose 5.0% but H2 EBITDA turned negative and operating cash flow fell 85%, leaving net debt at 12.8x EBITDA.
Published 23 April 2026
Read briefingHeadline growth reflects the Dairyworks acquisition while infant formula volumes fell 16% and inventory days reached 111.4, above the historical
Published 23 April 2026
Read briefingGet full NZX result briefings by email as new coverage is published.